Bayer awarded Amerinet deal

AuntMinnie.com staff writers
Apr 13, 2008

Bayer HealthCare Pharmaceuticals of Wayne, NJ, has received a two-year supply contract for its Magnevist and Ultravist contrast agents from group purchasing organization Amerinet.

The agreement is in effect through 2010 and covers both Magnevist (gadopentetate dimeglumine) and Ultravist (iopromide) in multiple quantities. The St. Louis-based Amerinet serves more than 26,000 acute and nonacute healthcare providers nationwide.

Related Reading

Bayer announces ship date for VistaTrak, March 13, 2008

Bayer inks molecular imaging deal, February 20, 2008

Bayer launches VistaTrak at RSNA show, December 3, 2007

Bayer HealthCare secures 3-year MRI contract, November 9, 2007

Bayer Schering Pharma licenses Avid's imaging agent, June 19, 2007

Copyright © 2008 AuntMinnie.com

Latest in Molecular Imaging
Kidneys
Kidneys appear to tolerate Lu-177 treatments
December 19, 2024
Prostate Imaging
African American men respond more favorably to Ra-223 therapy
December 17, 2024
Theranostics for neuroendocrine tumors: Glenda’s journey
Sponsored
Theranostics for neuroendocrine tumors: Glenda’s journey
December 1, 2024
PET/CT images of F-18 AlF-NOTA-BCP137 in patients with hepatocellular carcinoma (HCC) and immunofluorescence analysis of patient tissues. (A) F-18 AlF-NOTA-BCP137 PET/CT images before and after immunotherapy for patient 1 and patient 2. (B) F-18 AlF-NOTA-BCP137 PET/CT and MR images of patient 3 (left panels) after one cycle of immunotherapy. PET images showed higher uptake by tumor and spleen, and PET result was evaluated as positive; therefore, the patient was considered to be responder to treatment and underwent surgical resection. Representative images of hematoxylin and eosin (HE) staining and multiplex immunofluorescence of CD8 and CD137 (right panels) in HCC tumor and adjacent normal tissues of patient 3 after surgery. Nuclei were stained with 4′,6-diamidino-2-phenylindole. Primary tumors are indicated by white arrows, and increased thyroid uptake is indicated by red arrow in PET images. Image courtesy of the Journal of Nuclear Medicine.
Immuno-PET tracer shows promise in patients with liver cancer
December 12, 2024
Related Stories
187x200 Am Logo
Companies
AuntMinnie.com
Rsna
Market research reports
RSNA
2008 04 10 14 08 36 706
Nuclear Medicine
Cedars-Sinai explores PET's future in nuclear cardiology
Theranostics for neuroendocrine tumors: Glenda’s journey
Sponsor Content
Theranostics for neuroendocrine tumors: Glenda’s journey
More in Molecular Imaging
Kidneys appear to tolerate Lu-177 treatments
By Will Morton
Kidney-absorbed doses of lutetium-177 (Lu-177)-based treatments for prostate cancer and neuroendocrine tumors appear to be below toxicity thresholds.
December 19, 2024
Kidneys
African American men respond more favorably to Ra-223 therapy
By Will Morton
African American men with metastatic castrate-resistant prostate cancer may respond more favorably than white men to treatment with radium-223.
December 17, 2024
Prostate Imaging
PET visualizes acute graft vs. host disease
By Will Morton
F-18 fluorothymidine PET can identify early acute gastrointestinal graft versus host disease after patients undergo bone marrow transplants.
December 16, 2024
F-18 FLT-PET imaging of gastrointestinal GVHD. Examples of F-18 FLT uptake in a participant with no GVHD (left) and a participant with acute GVHD and uptake in the jejunum and ileum (right). Arrows denote increased uptake in the GI tract. Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of RSNA.
Immuno-PET tracer shows promise in patients with liver cancer
By Will Morton
A new PET radiotracer has the potential for visualizing responses in liver cancer patients undergoing immunotherapy.
December 12, 2024
PET/CT images of F-18 AlF-NOTA-BCP137 in patients with hepatocellular carcinoma (HCC) and immunofluorescence analysis of patient tissues. (A) F-18 AlF-NOTA-BCP137 PET/CT images before and after immunotherapy for patient 1 and patient 2. (B) F-18 AlF-NOTA-BCP137 PET/CT and MR images of patient 3 (left panels) after one cycle of immunotherapy. PET images showed higher uptake by tumor and spleen, and PET result was evaluated as positive; therefore, the patient was considered to be responder to treatment and underwent surgical resection. Representative images of hematoxylin and eosin (HE) staining and multiplex immunofluorescence of CD8 and CD137 (right panels) in HCC tumor and adjacent normal tissues of patient 3 after surgery. Nuclei were stained with 4′,6-diamidino-2-phenylindole. Primary tumors are indicated by white arrows, and increased thyroid uptake is indicated by red arrow in PET images. Image courtesy of the Journal of Nuclear Medicine.
MGH's Mahmood named new RSNA president
By AuntMinnie.com staff writers
Mahmood's primary research for the past 30 years has been in molecular imaging and its application to guide precision medicine.
December 6, 2024
Rsna Mahmood Thumbnail
New SPECT-based coronary risk score developed for women
By Will Morton
A new risk score based on SPECT imaging and other variables can accurately predict risks for women of major adverse cardiovascular events.
December 6, 2024
Heart Infection
PET/CT superior to CT in detecting bone metastases
By Will Morton
F-18 FDG-PET/CT performs better and is more cost-effective than CT in determining biopsy sites for suspected bone metastases.
November 26, 2024
Cancer
PET scan times can be reduced in Alzheimer’s patients
By Will Morton
F-18 florbetaben PET scans for diagnosing Alzheimer’s disease can be reduced from 20 minutes to five minutes without losing accuracy.
November 25, 2024
Patient Elderly Confused Headache
PET links chronic stress to aggressive endometrial cancer
By Will Morton
Brain activity related to chronic stress may be associated with the aggressiveness of tumors in women with endometrial cancer.
November 19, 2024
Pet Amygdala Thumbnail
FAPI-PET/CT superior to FDG-PET/CT in assessing liver cancer
By Will Morton
A recent study suggests that PET/CT imaging with a FAPI radiotracer is superior to F-18 FDG-PET/CT for assessing patients with liver cancer.
November 18, 2024
Two cases of pathologically confirmed intrahepatic cholangiocarcinomas in 68-year-old male patients. In both cases (A-H, case 1; I-P, case 2), CT scans (B, F, case 1; J, N, case 2) revealed intrahepatic bile duct dilation and suspected nodular lesions. While F-18 FDG PET/CT (A, C, D, case 1; I, K, L, case 2) failed to demonstrate abnormal tracer uptake (SUVmax 3.5, TBR 1.3 in Case 1; SUVmax 2.6, TBR 1.2 in Case 2), F-18 FAPI-04 PET/CT (E, G, H, case 1; M, O, P, case 2 ) showed positive uptake in the nodular lesions (SUVmax 9.7, TBR 3.5 in Case 1; SUVmax 9.6, TBR 3.3 in Case 2). Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of BMC Cancer.
New PET tracer shows promise in patients with kidney cancer
By Will Morton
A new PET radiotracer could offer a viable strategy for detecting primary tumors, involved lymph nodes, and distant metastases in patients with clear cell renal cell carcinoma.
November 14, 2024
Representative maximum-intensity projections of five patients (patients 3, 5, 7, 10, and 11) comparing Ga-68 NYM046 and F-18 FDG. Both tracers showed specific retention in bone and lymph node metastases (patients 10 and 11). Ga-68 NYM046 PET/CT outperformed F-18 FDG PET/CT in detecting primary tumors, lung metastases, and pleural metastases (patients 3, 5, 7, and 11). Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of the Journal of Nuclear Medicine.
SPECT/CT predicts treatment response in Pluvicto patients
By Will Morton
SPECT/CT scans taken just four hours after patients begin Lu-177 PSMA-617 treatment can help assess treatment responses.
November 1, 2024
Pluvicto Spect Ct Response Thumbnail
Page 1 of 599
Next Page